Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

OBJECTIVE: The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcom...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Gut
Prif Awduron: Lee, Sung Won, Kwon, Jung Hyun, Lee, Hae Lim, Yoo, Sun Hong, Nam, Hee Chul, Sung, Pil Soo, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, Han, Nam Ik, Jang, Jeong Won
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2020
Pynciau:
Hepatology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306978/
https://ncbi.nlm.nih.gov/pubmed/31672838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2019-318947
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg